PharmaCyte Biotech (OTCMKTS:PMCBD) Trading 0.4% Higher
PharmaCyte Biotech (OTCMKTS:PMCBD) Trading 0.4% Higher
PharmaCyte Biotech, Inc is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes.PharmaCyte Biotech Inc (OTCMKTS:PMCBD – Get Rating)'s stock price traded up 0.4% during trading on Tuesday . The stock traded as high as $2.88 and last traded at $2.84. 33,197 shares changed hands during mid-day trading, an increase of 276% from the average session volume of 8,831 shares. The stock had previously closed at $2.83.
藥典生物科技股份有限公司（OTCMKTS：PMCBD — 獲取評級）的股價在周二交易期間上漲了 0.4%。該股價高達 2.88 美元，最後交易價為 2.84 美元。33,197 股在中間交易期間變手，較 8,831 股的平均交易量增加了 276%。該股票之前已收盤 2.83 美元。
PharmaCyte Biotech Price Performance
藥典生技價格表現
The company's 50 day simple moving average is $2.94 and its 200 day simple moving average is $2.86.
該公司的 50 天簡單移動平均線為 2.94 美元，其 200 天的簡單移動平均線為 2.86 美元。
PharmaCyte Biotech Company Profile
藥典生物科技公司簡介
(Get Rating)
(取得評分)
PharmaCyte Biotech, Inc is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes.
PharhySyte 生物科技股份有限公司是一家臨床階段的生物技術公司，致力於癌症和糖尿病治療的開發和商業化。它專注於一種專有的基於纖維素的活細胞封裝技術，稱為 Cell-in-a-Box，該技術將用作開發無法手術的胰腺癌和其他實體癌性腫瘤以及糖尿病治療的平台。
Featured Articles
特色文章
- Get a free copy of the StockNews.com research report on PharmaCyte Biotech (PMCBD)
- After an Earnings Blowout, Is Ciena Stock a Buying Opportunity?
- Meta Breaks Out Of A Base, Looks Like A Growth Stock Again
- Here's Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
- The Bottom Is In For McCormick & Company
- Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
- 獲取有關藥物學生物技術研究報告的免費副本
- 盈利井噴後，Ciena 股票是一個購買機會嗎？
- Meta 突破了基礎，看起來再次成長股
- 這就是為什麼維京療法在肥胖症藥物數據上漲了 50％ 以上的原因
- 底部是在麥考密克 & 公司
- 沃爾格林靴子聯盟：藍籌，高收益周轉故事
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
接收有關藥劑生物技術日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關 Pharyyte 生物技術及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。
